Pharmaceuticals

Impact Of Rising Type 1 Diabetes Prevalence On The Growth Of The Is Supporting Expansion In The Gastric Cancer Therapy Market

April 30, 2026April 30, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Level Of Market Value Growth Is Predicted For The Gastric Cancer Therapy Market From 2026 To 2030?

The gastric cancer therapy market size has experienced strong growth in recent years. It is forecast to increase from $4.5 billion in 2025 to $4.92 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 9.3%. The expansion observed in the historic period can be ascribed to factors such as limited targeted therapy availability, continued reliance on conventional chemotherapy and surgery, the rising prevalence of gastric cancer, the increasing hospital oncology infrastructure, and growing awareness of early detection programs.

The gastric cancer therapy market is projected to experience substantial expansion over the upcoming years. This market is anticipated to reach a value of $6.96 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 9.1%. The expansion during the projected timeframe is attributable to several factors, including the emergence of new immunotherapies and checkpoint inhibitors, a surge in the acceptance of precision medicine, the broadening of outpatient oncology offerings, increased funding for gastric cancer studies, and the incorporation of digital health instruments for tracking patient progress. Key trends expected in this period encompass a greater uptake of targeted and individualized treatments, an increase in the application of combination therapy methods, the advancement of programs for early diagnosis and screening, the wider availability of home care and ambulatory treatment choices, and an emphasis on minimizing side effects while enhancing the quality of life for patients.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25767&type=smp

Which Factors Are Influencing The Growth Of The Gastric Cancer Therapy Market?

The increasing occurrence of helicobacter pylori infection is anticipated to fuel the expansion of the gastric cancer therapy market in the coming years. This bacterial infection predominantly impacts the stomach lining and is a primary factor behind chronic gastritis and gastric cancer. The upward trend in helicobacter pylori infection is largely attributed to inadequate sanitation, as insufficient hygiene and tainted food or water sources facilitate its oral-oral or fecal-oral transmission. Gastric cancer therapy aids in diminishing the risk of gastric cancer resulting from H. pylori by treating the infection, reducing related stomach inflammation and cell damage, and preventing the advancement of chronic gastritis and atrophic changes that can lead to malignant transformation of the gastric mucosa. For instance, in November 2024, according to the report published by the Government of Canada, a Canada-based government administration, as of January 2023, the recurrence rate of H. pylori infection is estimated to be up to 19%, although it varies based on geographic region and age. Consequently, the growing prevalence of helicobacter pylori infection is propelling the growth of the gastric cancer therapy market.

What Are The Different Segment Types In The Gastric Cancer Therapy Market Segment Breakdown?

The gastric cancer therapy market covered in this report is segmented –

1) By Therapy Type: Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Surgery

2) By Drug Class: Cytotoxic Agents, Monoclonal Antibodies, Tyrosine Kinase Inhibitors, Checkpoint Inhibitors, Miscellaneous Agents

3) By Administration Route: Oral, Intravenous, Intramuscular, Subcutaneous

4) By Stage of Disease: Early Stage, Locally Advanced Stage, Metastatic Stage

5) By End User: Hospitals, Oncology Clinics, Ambulatory Surgical Centers, Research Institutions, Home Care Settings

Subsegments:

1) By Chemotherapy: Neoadjuvant Chemotherapy (NAC), Adjuvant Chemotherapy (AC), Palliative Chemotherapy (PC), Combination Chemotherapy, Monotherapy

2) By Targeted Therapy: Human Epidermal Growth Factor Receptor 2 (HER2) Targeted Therapy, Vascular Endothelial Growth Factor (VEGF) Inhibitors, Fibroblast Growth Factor Receptor (FGFR) Inhibitors, Mesenchymal-Epithelial Transition (MET) Inhibitors, Claudin 18 Isoform 2 Inhibitors

3) By Immunotherapy: Immune Checkpoint Inhibitors, Cancer Vaccines, Adoptive Cell Transfer, Cytokine Therapy, Combination Immunotherapy

4) By Radiation Therapy: External Beam Radiation Therapy (EBRT), Intensity-Modulated Radiation Therapy (IMRT), Three-Dimensional Conformal Radiation Therapy (3D-CRT), Brachytherapy

5) By Surgery: Endoscopic Mucosal Resection (EMR), Endoscopic Submucosal Dissection (ESD), Subtotal Gastrectomy, Total Gastrectomy, Lymphadenectomy

What Trends Are Transforming The Gastric Cancer Therapy Market?

Leading firms within the gastric cancer therapy market are concentrating on creating novel treatments, like combination therapy, aiming to boost treatment effectiveness and patient results. This approach, combination therapy, entails employing two or more therapeutic methods, including chemotherapy, targeted therapy, or immunotherapy, concurrently to augment their combined efficacy. As an illustration, during December 2024, BeOne Medicines Ltd., a pharmaceutical company from China previously known as BeiGene, secured approval from the U.S. Food and Drug Administration (FDA) for Tevimbra (tislelizumab-jsgr) when used alongside platinum- and fluoropyrimidine-based chemotherapy. This approval is for the initial treatment of adults suffering from unresectable or metastatic HER2-negative gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, specifically where tumors express PD-L1 (=1). The basis for this approval stemmed from the Phase 3 RATIONALE-305 trial’s data, which clearly showed that the combined treatment substantially extended median overall survival to 15.0 months, an increase from 12.9 months when only chemotherapy was administered, thereby signifying a 20% decrease in mortality risk. This significant achievement underscores an increasing pattern among prominent pharmaceutical companies: to invest in novel, multimodal treatment approaches that incorporate immunotherapy with standard chemotherapy regimens. The goal is to elevate clinical outcomes, slow the advancement of the disease, and boost survival rates for individuals with advanced gastric cancer.

Who Are The Well-Known Companies In The Gastric Cancer Therapy Market?

Major companies operating in the gastric cancer therapy market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, Eli Lilly and Company, Amgen Inc., Astellas Pharma Inc., Jiangsu Hengrui Pharmaceuticals Co. Ltd., BeiGene Ltd., Celltrion Healthcare Co. Ltd., Hutchison MediPharma Limited, Shanghai Henlius Biotech Inc.

Get The Full Gastric Cancer Therapy Market Report:

https://www.thebusinessresearchcompany.com/report/gastric-cancer-therapy-global-market-report

Which Region Holds The Highest Market Share In The Gastric Cancer Therapy Market?

North America was the largest region in the gastric cancer therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastric cancer therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Gastric Cancer Therapy Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/gastric-cancer-therapy-global-market-report

Browse Through More Reports Similar to the Global Gastric Cancer Therapy Market 2026, By The Business Research Company

Gastric Cancer Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/gastric-cancer-drugs-global-market-report

Gastric Cancer Diagnostic Procedure Market Report 2026

https://www.thebusinessresearchcompany.com/report/gastric-cancer-diagnostic-procedure-global-market-report

Intestine Cancer Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/intestine-cancer-therapeutics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795